Jennifer Rachel Cochran - Publications

Affiliations: 
Bioengineering Stanford University, Palo Alto, CA 
Area:
Bioengineering
Website:
https://profiles.stanford.edu/jennifer-cochran

74 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Murty S, Labanieh L, Murty T, Gowrishankar G, Haywood T, Alam IS, Beinat C, Robinson E, Aalipour A, Klysz DD, Cochran JR, Majzner RG, Mackall CL, Gambhir SS. PET reporter gene imaging and ganciclovir-mediated ablation of chimeric antigen receptor T-cells in solid tumors. Cancer Research. PMID 32958548 DOI: 10.1158/0008-5472.Can-19-3579  0.358
2020 Mehta N, Maddineni S, Kelly RL, Lee RB, Hunter SA, Silberstein JL, Parra Sperberg RA, Miller CL, Rabe A, Labanieh L, Cochran JR. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA. Scientific Reports. 10: 15171. PMID 32938950 DOI: 10.1038/S41598-020-71519-4  0.39
2020 Kim JW, Marquez CP, Sperberg RAP, Wu J, Bae WG, Huang PS, Sweet-Cordero EA, Cochran JR. Engineering a potent receptor superagonist or antagonist from a novel IL-6 family cytokine ligand. Proceedings of the National Academy of Sciences of the United States of America. PMID 32522868 DOI: 10.1073/Pnas.1922729117  0.36
2019 Kim JW, Marquez CP, Kostyrko K, Koehne AL, Marini K, Simpson DR, Lee AG, Leung SG, Sayles LC, Shrager J, Ferrer I, Paz-Ares L, Gephart MH, Vicent S, Cochran JR, et al. Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma. Nature Medicine. PMID 31700175 DOI: 10.1038/S41591-019-0612-2  0.346
2019 Mehta N, Maddineni S, Mathews II, Andres Parra Sperberg R, Huang PS, Cochran JR. Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation. Cell Reports. 28: 2509-2516.e5. PMID 31484064 DOI: 10.1016/J.Celrep.2019.07.073  0.356
2019 Van Agthoven JF, Shams H, Cochran FV, Alonso JL, Kintzing JR, Garakani K, Adair BD, Xiong JP, Mofrad MRK, Cochran JR, Arnaout MA. Structural Basis of the Differential Binding of Engineered Knottins to Integrins αVβ3 and α5β1. Structure (London, England : 1993). PMID 31353240 DOI: 10.1016/J.Str.2019.06.011  0.317
2018 Mitchell AC, Kannan D, Hunter SA, Parra Sperberg RA, Chang CH, Cochran JR. Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein. The Journal of Biological Chemistry. PMID 29386351 DOI: 10.1074/Jbc.M117.815142  0.338
2018 Marquez C, Kim J, Giaccia A, Cochran J, Sweet-Cordero A. Abstract 3918: Targeting the CLCF1-CNTFR signaling axis using directed evolution for lung cancer therapy Cancer Research. 78: 3918-3918. DOI: 10.1158/1538-7445.Am2018-3918  0.344
2017 Thayaparan T, Petrovic RM, Achkova DY, Zabinski T, Davies DM, Klampatsa A, Parente-Pereira AC, Whilding LM, van der Stegen SJ, Woodman N, Sheaff M, Cochran JR, Spicer JF, Maher J. CAR T-cell immunotherapy of MET-expressing malignant mesothelioma. Oncoimmunology. 6: e1363137. PMID 29209570 DOI: 10.1080/2162402X.2017.1363137  0.438
2017 Mitchell AC, Alford SC, Hunter SA, Kannan D, Parra Sperberg RA, Chang CH, Cochran JR. Development of a Protease Biosensor Based on a Dimerization-Dependent Red Fluorescent Protein. Acs Chemical Biology. PMID 29125730 DOI: 10.1021/Acschembio.7B00715  0.323
2017 Kwan BH, Zhu EF, Tzeng A, Sugito HR, Eltahir AA, Ma B, Delaney MK, Murphy PA, Kauke MJ, Angelini A, Momin N, Mehta NK, Maragh AM, Hynes RO, Dranoff G, ... Cochran JR, et al. Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. The Journal of Experimental Medicine. PMID 28473400 DOI: 10.1084/Jem.20160831  0.556
2017 Kim JW, Cochran JR. Targeting ligand-receptor interactions for development of cancer therapeutics. Current Opinion in Chemical Biology. 38: 62-69. PMID 28371692 DOI: 10.1016/J.Cbpa.2017.03.010  0.335
2017 Lim S, Glasgow JE, Filsinger Interrante M, Storm EM, Cochran JR. Dual display of proteins on the yeast cell surface simplifies quantification of binding interactions and enzymatic bioconjugation reactions. Biotechnology Journal. PMID 28299901 DOI: 10.1002/Biot.201600696  0.361
2016 Lim S, Chen B, Kariolis MS, Dimov IK, Baer TM, Cochran JR. Engineering High Affinity Protein-Protein Interactions Using a High-Throughput Microcapillary Array Platform. Acs Chemical Biology. PMID 27997117 DOI: 10.1021/Acschembio.6B00794  0.357
2016 Kariolis MS, Miao YR, Diep A, Nash SE, Olcina MM, Jiang D, Jones DS, Kapur S, Mathews II, Koong AC, Rankin EB, Cochran JR, Giaccia AJ. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies. The Journal of Clinical Investigation. PMID 27893463 DOI: 10.1172/Jci85610  0.351
2016 Kintzing JR, Filsinger Interrante MV, Cochran JR. Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment. Trends in Pharmacological Sciences. PMID 27836202 DOI: 10.1016/J.Tips.2016.10.005  0.362
2016 Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM, Kumari S, Kelly RL, Kwan BH, Abraham W, Hu K, ... ... Cochran JR, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nature Medicine. PMID 27775706 DOI: 10.1038/Nm.4200  0.544
2016 Kintzing JR, Cochran JR. Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles. Current Opinion in Chemical Biology. 34: 143-150. PMID 27642714 DOI: 10.1016/J.Cbpa.2016.08.022  0.342
2016 Hunter SA, Cochran JR. Cell-Binding Assays for Determining the Affinity of Protein-Protein Interactions: Technologies and Considerations. Methods in Enzymology. 580: 21-44. PMID 27586327 DOI: 10.1016/Bs.Mie.2016.05.002  0.338
2016 Cox N, Kintzing JR, Smith M, Grant GA, Cochran JR. Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. Angewandte Chemie (International Ed. in English). PMID 27304709 DOI: 10.1002/Anie.201603488  0.347
2016 Glasgow JE, Salit ML, Cochran JR. In Vivo Site-Specific Protein Tagging with Diverse Amines Using an Engineered Sortase Variant. Journal of the American Chemical Society. PMID 27280683 DOI: 10.1021/Jacs.6B03836  0.324
2016 Currier NV, Ackerman SE, Kintzing JR, Chen R, Interrante MF, Steiner A, Sato AK, Cochran JR. Targeted Drug Delivery with an Integrin-Binding Knottin-Fc-MMAF Conjugate Produced by Cell-Free-Protein Synthesis. Molecular Cancer Therapeutics. PMID 27197305 DOI: 10.1158/1535-7163.Mct-15-0881  0.331
2016 Cox N, Kintzing JR, Smith M, Grant GA, Cochran JR. Inside Cover: Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation (Angew. Chem. Int. Ed. 34/2016) Angewandte Chemie International Edition. 55: 9796-9796. DOI: 10.1002/Anie.201605483  0.328
2016 Cox N, Kintzing JR, Smith M, Grant GA, Cochran JR. Innentitelbild: Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation (Angew. Chem. 34/2016) Angewandte Chemie. 128: 9950-9950. DOI: 10.1002/Ange.201605483  0.33
2015 Chen B, Lim S, Kannan A, Alford SC, Sunden F, Herschlag D, Dimov IK, Baer TM, Cochran JR. High-throughput analysis and protein engineering using microcapillary arrays. Nature Chemical Biology. PMID 26641932 DOI: 10.1038/Nchembio.1978  0.349
2015 Mitchell AC, Briquez PS, Hubbell JA, Cochran JR. Engineering growth factors for regenerative medicine applications. Acta Biomaterialia. PMID 26555377 DOI: 10.1016/J.Actbio.2015.11.007  0.352
2015 Cherf GM, Cochran JR. Applications of Yeast Surface Display for Protein Engineering. Methods in Molecular Biology (Clifton, N.J.). 1319: 155-75. PMID 26060074 DOI: 10.1007/978-1-4939-2748-7_8  0.305
2015 Kim JW, Cochran FV, Cochran JR. A chemically cross-linked knottin dimer binds integrins with picomolar affinity and inhibits tumor cell migration and proliferation. Journal of the American Chemical Society. 137: 6-9. PMID 25486381 DOI: 10.1021/Ja508416E  0.367
2014 Ackerman SE, Wilson CM, Kahn SA, Kintzing JR, Jindal DA, Cheshier SH, Grant GA, Cochran JR. A Bioengineered Peptide that Localizes to and Illuminates Medulloblastoma: A New Tool with Potential for Fluorescence-Guided Surgical Resection. Cureus. 6. PMID 28729960 DOI: 10.7759/Cureus.207  0.333
2014 Liu CJ, Jones DS, Tsai PC, Venkataramana A, Cochran JR. An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist. Febs Letters. 588: 4831-7. PMID 25451235 DOI: 10.1016/J.Febslet.2014.11.018  0.616
2014 Kariolis MS, Miao YR, Jones DS, Kapur S, Mathews II, Giaccia AJ, Cochran JR. An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. Nature Chemical Biology. 10: 977-83. PMID 25242553 DOI: 10.1038/Nchembio.1636  0.375
2014 Ackerman SE, Currier NV, Bergen JM, Cochran JR. Cystine-knot peptides: emerging tools for cancer imaging and therapy. Expert Review of Proteomics. 11: 561-72. PMID 25163524 DOI: 10.1586/14789450.2014.932251  0.335
2013 Moore SJ, Hayden Gephart MG, Bergen JM, Su YS, Rayburn H, Scott MP, Cochran JR. Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma. Proceedings of the National Academy of Sciences of the United States of America. 110: 14598-603. PMID 23950221 DOI: 10.1073/Pnas.1311333110  0.335
2013 Kariolis MS, Kapur S, Cochran JR. Beyond antibodies: using biological principles to guide the development of next-generation protein therapeutics. Current Opinion in Biotechnology. 24: 1072-7. PMID 23587963 DOI: 10.1016/J.Copbio.2013.03.017  0.336
2013 Moore SJ, Leung CL, Norton HK, Cochran JR. Engineering agatoxin, a cystine-knot peptide from spider venom, as a molecular probe for in vivo tumor imaging. Plos One. 8: e60498. PMID 23573262 DOI: 10.1371/Journal.Pone.0060498  0.374
2013 Jiang H, Moore SJ, Liu S, Liu H, Miao Z, Cochran FV, Liu Y, Tian M, Cochran JR, Zhang H, Cheng Z. A novel radiofluorinated agouti-related protein for tumor angiogenesis imaging. Amino Acids. 44: 673-81. PMID 22945905 DOI: 10.1007/S00726-012-1391-Y  0.316
2012 Jiang L, Miao Z, Kimura RH, Silverman AP, Ren G, Liu H, Lu H, Cochran JR, Cheng Z. 111In-labeled cystine-knot peptides based on the Agouti-related protein for targeting tumor angiogenesis. Journal of Biomedicine & Biotechnology. 2012: 368075. PMID 22570527 DOI: 10.1155/2012/368075  0.351
2012 Moore SJ, Cochran JR. Engineering knottins as novel binding agents. Methods in Enzymology. 503: 223-51. PMID 22230571 DOI: 10.1016/B978-0-12-396962-0.00009-4  0.372
2012 Moore SJ, Leung CL, Cochran JR. Knottins: Disulfide-bonded therapeutic and diagnostic peptides Drug Discovery Today: Technologies. 9. DOI: 10.1016/J.Ddtec.2011.07.003  0.324
2011 Liu S, Liu H, Ren G, Kimura RH, Cochran JR, Cheng Z. PET Imaging of Integrin Positive Tumors Using F Labeled Knottin Peptides. Theranostics. 1: 403-12. PMID 22211146 DOI: 10.7150/Thno/V01P0403  0.337
2011 Lui BH, Cochran JR, Swartz JR. Discovery of improved EGF agonists using a novel in vitro screening platform. Journal of Molecular Biology. 413: 406-15. PMID 21888916 DOI: 10.1016/J.Jmb.2011.08.028  0.349
2011 Papo N, Silverman AP, Lahti JL, Cochran JR. Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin. Proceedings of the National Academy of Sciences of the United States of America. 108: 14067-72. PMID 21825147 DOI: 10.1073/Pnas.1016635108  0.329
2011 Jones DS, Tsai PC, Cochran JR. Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists. Proceedings of the National Academy of Sciences of the United States of America. 108: 13035-40. PMID 21788476 DOI: 10.1073/Pnas.1102561108  0.627
2011 Lahti JL, Lui BH, Beck SE, Lee SS, Ly DP, Longaker MT, Yang GP, Cochran JR. Engineered epidermal growth factor mutants with faster binding on-rates correlate with enhanced receptor activation. Febs Letters. 585: 1135-9. PMID 21439278 DOI: 10.1016/J.Febslet.2011.03.044  0.374
2011 Kimura RH, Jones DS, Jiang L, Miao Z, Cheng Z, Cochran JR. Functional mutation of multiple solvent-exposed loops in the Ecballium elaterium trypsin inhibitor-II cystine knot miniprotein. Plos One. 6: e16112. PMID 21364742 DOI: 10.1371/Journal.Pone.0016112  0.315
2011 Silverman AP, Kariolis MS, Cochran JR. Cystine-knot peptides engineered with specificities for α(IIb)β(3) or α(IIb)β(3) and α(v)β(3) integrins are potent inhibitors of platelet aggregation. Journal of Molecular Recognition : Jmr. 24: 127-35. PMID 21194123 DOI: 10.1002/Jmr.1036  0.301
2011 Jiang L, Miao Z, Kimura RH, Liu H, Cochran JR, Culter CS, Bao A, Li P, Cheng Z. Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. 38: 613-22. PMID 21153409 DOI: 10.1007/S00259-010-1684-X  0.374
2010 Atmaja B, Lui BH, Hu Y, Beck SE, Frank CW, Cochran JR. Targeting of Cancer Cells Using Quantum Dot-Polypeptide Hybrid Assemblies that Function as Molecular Imaging Agents and Carrier Systems. Advanced Functional Materials. 20: 4091-4097. PMID 25750609 DOI: 10.1002/Adfm.201000732  0.326
2010 Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR, Gambhir SS. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 433-40. PMID 20150258 DOI: 10.2967/Jnumed.109.068007  0.311
2010 Kimura RH, Miao Z, Cheng Z, Gambhir SS, Cochran JR. A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. Bioconjugate Chemistry. 21: 436-44. PMID 20131753 DOI: 10.1021/Bc9003102  0.321
2010 Jiang L, Kimura RH, Miao Z, Silverman AP, Ren G, Liu H, Li P, Gambhir SS, Cochran JR, Cheng Z. Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 251-8. PMID 20124048 DOI: 10.2967/Jnumed.109.069831  0.362
2009 Miao Z, Ren G, Liu H, Kimura RH, Jiang L, Cochran JR, Gambhir SS, Cheng Z. An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. Bioconjugate Chemistry. 20: 2342-7. PMID 19908826 DOI: 10.1021/Bc900361G  0.304
2009 Kimura RH, Levin AM, Cochran FV, Cochran JR. Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. Proteins. 77: 359-69. PMID 19452550 DOI: 10.1002/Prot.22441  0.381
2009 Garrett TP, Burgess AW, Gan HK, Luwor RB, Cartwright G, Walker F, Orchard SG, Clayton AH, Nice EC, Rothacker J, Catimel B, Cavenee WK, Old LJ, Stockert E, Ritter G, ... ... Cochran JR, et al. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proceedings of the National Academy of Sciences of the United States of America. 106: 5082-7. PMID 19289842 DOI: 10.1073/Pnas.0811559106  0.384
2009 Kimura RH, Cheng Z, Gambhir SS, Cochran JR. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Research. 69: 2435-42. PMID 19276378 DOI: 10.1158/0008-5472.Can-08-2495  0.356
2009 Silverman AP, Levin AM, Lahti JL, Cochran JR. Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities. Journal of Molecular Biology. 385: 1064-75. PMID 19038268 DOI: 10.1016/J.Jmb.2008.11.004  0.326
2009 Ly D, Lahti J, Beck S, Lee S, Longaker M, Yang G, Cochran J. 220. Enhanced Biological Function of Engineered EGF is Correlated With Faster On-Rates of Receptor Binding Journal of Surgical Research. 151: 270-271. DOI: 10.1016/J.Jss.2008.11.262  0.335
2009 Willmann JK, Kimura RH, Cochran J, Gambhir SS. CMR2009: 1.03: Molecular contrast agents for ultrasound imaging of tumor angiogenesis: engineering of novel binding ligands Contrast Media & Molecular Imaging. 4: 260-261. DOI: 10.1002/Cmmi.298  0.309
2008 Jones DS, Silverman AP, Cochran JR. Developing therapeutic proteins by engineering ligand-receptor interactions. Trends in Biotechnology. 26: 498-505. PMID 18675482 DOI: 10.1016/J.Tibtech.2008.05.009  0.382
2006 Cochran JR, Kim YS, Lippow SM, Rao B, Wittrup KD. Improved mutants from directed evolution are biased to orthologous substitutions. Protein Engineering, Design & Selection : Peds. 19: 245-53. PMID 16740523 DOI: 10.1093/Protein/Gzl006  0.659
2006 Kim YS, Bhandari R, Cochran JR, Kuriyan J, Wittrup KD. Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. Proteins. 62: 1026-35. PMID 16355407 DOI: 10.1002/Prot.20618  0.576
2005 Chao G, Cochran JR, Dane Wittrup K. Corrigendum to: “Fine Epitope Mapping of anti-Epidermal Growth Factor Receptor Antibodies Through Random Mutagenesis and Yeast Surface Display” [J. Mol. Biol. (2004) 342, 539–550] Journal of Molecular Biology. 346: 1455. DOI: 10.1016/J.Jmb.2005.01.010  0.305
2004 Chao G, Cochran JR, Wittrup KD. Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. Journal of Molecular Biology. 342: 539-50. PMID 15327953 DOI: 10.1016/J.Jmb.2004.07.053  0.569
2004 Cochran JR, Kim YS, Olsen MJ, Bhandari R, Wittrup KD. Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. Journal of Immunological Methods. 287: 147-58. PMID 15099763 DOI: 10.1016/J.Jim.2004.01.024  0.584
2004 Johns TG, Adams TE, Cochran JR, Hall NE, Hoyne PA, Olsen MJ, Kim YS, Rothacker J, Nice EC, Walker F, Ritter G, Jungbluth AA, Old LJ, Ward CW, Burgess AW, et al. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. The Journal of Biological Chemistry. 279: 30375-84. PMID 15075331 DOI: 10.1074/Jbc.M401218200  0.584
2003 Feldhaus MJ, Siegel RW, Opresko LK, Coleman JR, Feldhaus JM, Yeung YA, Cochran JR, Heinzelman P, Colby D, Swers J, Graff C, Wiley HS, Wittrup KD. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nature Biotechnology. 21: 163-70. PMID 12536217 DOI: 10.1038/Nbt785  0.532
2002 Ge Q, Stone JD, Thompson MT, Cochran JR, Rushe M, Eisen HN, Chen J, Stern LJ. Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules. Proceedings of the National Academy of Sciences of the United States of America. 99: 13729-34. PMID 12374859 DOI: 10.1073/Pnas.212515299  0.738
2001 Stone JD, Cochran JR, Stern LJ. T-cell activation by soluble MHC oligomers can be described by a two-parameter binding model. Biophysical Journal. 81: 2547-57. PMID 11606269 DOI: 10.1016/S0006-3495(01)75899-7  0.624
2001 Cameron TO, Stone JD, Cochran JR, Stern LJ. TCR: losing its inhibitions? Trends in Immunology. 22: 479-80. PMID 11556322 DOI: 10.1016/S1471-4906(01)01996-2  0.505
2001 Cochran JR, Cameron TO, Stone JD, Lubetsky JB, Stern LJ. Receptor proximity, not intermolecular orientation, is critical for triggering T-cell activation. The Journal of Biological Chemistry. 276: 28068-74. PMID 11384988 DOI: 10.1074/Jbc.M103280200  0.615
2001 Cochran JR, Aivazian D, Cameron TO, Stern LJ. Receptor clustering and transmembrane signaling in T cells. Trends in Biochemical Sciences. 26: 304-10. PMID 11343923 DOI: 10.1016/S0968-0004(01)01815-1  0.605
2001 Cameron TO, Cochran JR, Yassine-Diab B, Sékaly RP, Stern LJ. Cutting edge: detection of antigen-specific CD4+ T cells by HLA-DR1 oligomers is dependent on the T cell activation state. Journal of Immunology (Baltimore, Md. : 1950). 166: 741-5. PMID 11145645 DOI: 10.4049/Jimmunol.166.2.741  0.577
2000 Cochran JR, Stern LJ. A diverse set of oligomeric class II MHC-peptide complexes for probing T-cell receptor interactions. Chemistry & Biology. 7: 683-96. PMID 10980449 DOI: 10.1016/S1074-5521(00)00019-3  0.624
2000 Cochran JR, Cameron TO, Stern LJ. The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. Immunity. 12: 241-50. PMID 10755611 DOI: 10.1016/S1074-7613(00)80177-6  0.614
Show low-probability matches.